A Clearer View from JPM 2026 – Day One
Here we are again. January means the JP Morgan Healthcare Conference and all eyes in the pharma and biotech space turn to San Francisco. Our Biomedtracker team is providing daily reports to bring you the highlights of each day’s activities. There’s loads to digest in the full Day One report, so here are a few […]
How Biotechs Can Win Capital in 2026: Highlights from Evaluate’s Financing Forum
January may be upon us but allow me one chance to look back at one of December’s highlights; Evaluate’s event that took place in London. Evaluate Financing Forum: Biotech Strategies for Accessing Capital saw more than 50 professionals from pharma, biotech and financing come together for a morning of networking and knowledge sharing about biotech […]
Three Things we Learned in our Unlocking Innovation in Pharma Webinar
There is life beyond ADCs and GLP-1s. Given the level of attention these particular areas have received in recent years, it can be hard to remember that – but it was a key message from our recent webinar, “Unlocking Innovation: What pharma deals reveal about tomorrow’s therapies”. Our business development and licensing experts investigated where […]
What Does Dealmaking Tell Us About the Therapies of Tomorrow?
Our upcoming Unlocking Innovation webinar analyzes dealmaking activity to identify mechanisms and technologies that have been trending in recent years, beyond ADCs or GLP-1s. While these two modalities have dominated headlines and investor interest, thanks to their blockbuster potential in oncology and metabolic disease, there’s a broader wave of innovation that could shape the future […]
It’s Time to Act: Why Trump is good for European Biopharma…
Call it a kick up the backside. For decades, Europe has failed to address its biopharma weaknesses – too little lab-to-drug translation, too little scale-up capital, non-existent public markets and penny-pinching drug budgets. Then came President Trump. Love him or hate him, his call-out of the US-EU drug pricing gap, his tariff-talk and his efforts […]
Ready for a Cliffhanger? Register for our Loss of Exclusivity Webinar
For the past few years, our annual World Preview report has included analysis of the potential scale of the 2025-2030 pharma patent cliff. It’s one of the features that garners the most questions from readers, particularly around how a potential loss of $300bn can sit alongside forecast growth of over 7% in the same time […]
Three Things We Learned in our Corporate-Level Competitive Intelligence Webinar
Our Competitive Intelligence consulting team has been busy recently. Fresh from presenting at Pharma CI, Kelly Chamberlain led our latest webinar, “Mind the Gap: Supporting Cross-Functional Teams with Corporate Level CI”. She was joined by Paul D’Souza and Amanda Micklus and Paul is straight off to Pharma Cimicon in Berlin to share his wisdom with […]
Enterprise-Level Peer Analysis: Solving a Gap in Competitive Intelligence
Recently, I was delighted to attend the Pharma CI event in Newark, NJ which brought together competitive intelligence (CI) leaders from across the pharmaceutical industry to tackle the key challenges that face CI teams every day. In addition to catching up with familiar faces and meeting new people, I had the pleasure of taking the […]
Strategic Deals and Investment Moves Influencing the GLP-1 Marketplace
While the rapid growth of the GLP-1 and obesity market presents enormous financial opportunities for life sciences companies, it also carries legal, regulatory, and reimbursement risks. With that in mind, Norstella were recently invited to present a session at the American Conference Institute Inaugural Summit on GLP-1 Law & Policy, Using deals data from Evaluate […]
Back from BIO: The Evolving Biotech Investment Landscape
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the state of play for biotechs in recent years. Fortunately, while this may be only a partial exaggeration, there were many more positive notes as well. Fresh from my third BIO International and after digesting […]
